ORMP Stock Overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
Oramed Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.50|
|52 Week High||US$31.54|
|52 Week Low||US$3.59|
|1 Month Change||-8.35%|
|3 Month Change||-47.98%|
|1 Year Change||-66.37%|
|3 Year Change||40.63%|
|5 Year Change||-45.98%|
|Change since IPO||2,374.89%|
Recent News & Updates
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|ORMP||US Pharmaceuticals||US Market|
Return vs Industry: ORMP underperformed the US Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: ORMP underperformed the US Market which returned -20.4% over the past year.
|ORMP Average Weekly Movement||15.2%|
|Pharmaceuticals Industry Average Movement||11.9%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ORMP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ORMP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
Oramed Pharmaceuticals Fundamentals Summary
|ORMP fundamental statistics|
Is ORMP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORMP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.03|
|Net Profit Margin||-1,466.04%|
How did ORMP perform over the long term?See historical performance and comparison
Is ORMP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ORMP?
Other financial metrics that can be useful for relative valuation.
|What is ORMP's n/a Ratio?|
Price to Book Ratio vs Peers
How does ORMP's PB Ratio compare to its peers?
|ORMP PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
LYRA Lyra Therapeutics
ANTX AN2 Therapeutics
IKNA Ikena Oncology
THRX Theseus Pharmaceuticals
ORMP Oramed Pharmaceuticals
Price-To-Book vs Peers: ORMP is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (2.3x).
Price to Earnings Ratio vs Industry
How does ORMP's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: ORMP is good value based on its Price-To-Book Ratio (1.1x) compared to the US Pharmaceuticals industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is ORMP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.1x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate ORMP's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ORMP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ORMP ($4.5) is trading below our estimate of fair value ($66.33)
Significantly Below Fair Value: ORMP is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORMP's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Oramed Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORMP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ORMP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ORMP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ORMP's revenue (64% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: ORMP's revenue (64% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORMP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Oramed Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORMP is currently unprofitable.
Growing Profit Margin: ORMP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORMP is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Accelerating Growth: Unable to compare ORMP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORMP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).
Return on Equity
High ROE: ORMP has a negative Return on Equity (-25.53%), as it is currently unprofitable.
Discover strong past performing companies
How is Oramed Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ORMP's short term assets ($143.6M) exceed its short term liabilities ($6.3M).
Long Term Liabilities: ORMP's short term assets ($143.6M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: ORMP is debt free.
Reducing Debt: ORMP has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORMP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ORMP has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 35.8% each year.
Discover healthy companies
What is Oramed Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORMP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORMP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORMP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORMP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ORMP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nadav Kidron (47 yo)
Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...
CEO Compensation Analysis
Compensation vs Market: Nadav's total compensation ($USD1.23M) is about average for companies of similar size in the US market ($USD1.76M).
Compensation vs Earnings: Nadav's compensation has been consistent with company performance over the past year.
Experienced Management: ORMP's management team is considered experienced (2.8 years average tenure).
Experienced Board: ORMP's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.7%.
Oramed Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: Oramed Pharmaceuticals Inc.
- Ticker: ORMP
- Exchange: NasdaqCM
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$173.538m
- Shares outstanding: 38.56m
- Website: https://www.oramed.com
- Oramed Pharmaceuticals Inc.
- 1185 Avenue of the Americas
- 3rd Floor
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.